55 related articles for article (PubMed ID: 26652966)
1. [Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].
Doležal T; Kruntorádová K
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S50-3. PubMed ID: 26652966
[TBL] [Abstract][Full Text] [Related]
2. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
Haluzík M; Adamíková A; Běhunčík M; Macko M; Štěpánová R
Vnitr Lek; 2018; 64(4):357-366. PubMed ID: 29791170
[TBL] [Abstract][Full Text] [Related]
5. [Treatment strategy of type 2 diabetes used in Czech Republic after metformin therapy failure].
Svačina Š; Ovesná P; Kuhn M; Nováčková M
Vnitr Lek; 2017; 63(10):647-657. PubMed ID: 29127747
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the development of metformin and sulfonylurea prescriptions in the Czech Republic].
Janíčková-Žďarská D; Honěk P; Dušek L; Pavlík T; Kvapil M
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S25-9. PubMed ID: 26652962
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
9. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Steen Carlsson K; Persson U
J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
[TBL] [Abstract][Full Text] [Related]
12. [The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003-2013 and came closer to the population average].
Brož J; Honěk P; Dušek L; Pavlík T; Kvapil M
Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S14-20. PubMed ID: 26652960
[TBL] [Abstract][Full Text] [Related]
13. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Dai X; Wang H; Jing Z; Fu P
Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
Trials; 2015 Nov; 16():496. PubMed ID: 26530718
[TBL] [Abstract][Full Text] [Related]
17. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
20. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
Suh HS; Kim JA; Lee IH
BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
